Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Frankincense essential oil + boswellic acid is a combination product derived from resin of Boswellia trees, primarily containing frankincense essential oil and its major active triterpenoid components known as boswellic acids (including β-boswellic acid, acetyl-β-boswellic acid, 11-keto-β-boswellic acid, and 3-acetyl-11-keto-β-boswellic acid)[5]. The combination is recognized for its anti-inflammatory, analgesic, immunomodulatory, antimicrobial, and some anticancer properties[1][3][5][6]. Mechanistically, boswellic acids primarily inhibit key inflammatory pathways (5-lipoxygenase, cyclooxygenase-2, proinflammatory cytokines), reduce leukotriene synthesis, suppress matrix metalloproteinases, and in cancer contexts, regulate apoptosis and cell cycle through modulation of NF-κB, VEGFR2, and AMPK/mTOR pathways[3][6]. Frankincense essential oil is typically used topically, by inhalation, or as a flavor for oral health, while boswellic acids are mainly consumed orally in standardized extract form. The combination may be found in dietary supplements or multi-ingredient products for inflammatory diseases, arthritis, asthma, gut disorders, or general immune support[1][2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on frankincense essential oil + boswellic acid.